ArticleCell & bioscience2026
Astrocytic VPS35 coordinates iron homeostasis with HIF1α-VEGFa signaling to prevent astrocytic ferroptosis and to promote neocortical angiogenesis.
Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Astrocytes coordinate neuronal activity with vascular development and metabolic homeostasis during postnatal brain maturation, yet the mechanisms enabling astrocytes to support angiogenesis remain elusive. VPS35, a core component of the retromer complex, regulates transmembrane protein trafficking and is implicated in multiple neurodegenerative diseases; however, its function in astrocytes is unknown. Here, we identify astrocytic VPS35 as a crucial regulator for astrocyte maturation and neurovascular development through its control of iron homeostasis and HIF1α-VEGFa signaling. Conditional deletion of Vps35 in astrocytes impaired astrocyte maturation and survival, as well as basal and activity-dependent angiogenesis, thus reducing cerebral blood flow, and inducing widespread vascular abnormalities in both cortical and meningeal vessels. Mechanistically, loss of astrocytic Vps35 resulted in intracellular iron accumulation, likely due to impaired ferroportin (FPN)-mediated iron export. Iron overload enhanced HIF1α hydroxylation and degradation, suppressing VEGFa expression and attenuating angiogenic responses. In parallel, excess iron induced astrocyte ferroptosis, characterized by increased lipid peroxidation, diminished antioxidant capacity, astrocyte loss, and impaired astrocyte maturation. Importantly, iron chelation reduced ferroptotic stress, restored HIF1α-VEGFa signaling, and rescued vascular density in mutant mice. Together, these findings establish astrocytic VPS35 as a critical integrator of endosomal protein trafficking, iron metabolism, and angiogenic signaling, and identify iron dysregulation as a central mechanism linking retromer dysfunction to impaired astrocyte and neurovascular development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.